Also found in: Medical.
NSABPNational Surgical Adjuvant Breast and Bowel Project (cancer treatment trial)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Another study, the NSABP B-32 phase-III trial, observed false negative rate of 9.8%, with 8.9% for T2 tumours and 10.3% for T1 tumours, and an accuracy of 97.3%5.
Dual blockade of HER2 with trastuzumab and lapatinib has been examined in the neoadjuvant treatment setting in 4 randomized studies (Table 1), comparing the activity of trastuzumab, lapatinib, or both with paclitaxel: the phase III NeoALTTO [81], the phase II CHER-LOB [82], the phase III NSABP B-41 [83], and the phase III CALGB 40601 [84].
(23.) Fisher ER, Dignam J, Tan-Chiu E, et al, for the National Surgical Adjuvant Breast Bowel Project (NSABP) Collaborating Investigators (1999), Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17.
Julian et al., "Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial," The Lancet, vol.
Technical outcomes of sentinel-lymphnode resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial.
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
pCR (Pathologic complete response) is the best indicator of efficacy of NACT which eventually also is predictor of DFS(Disease free survival) & OAS(Ovearall survival) as seen in trials like NSABP 18& 27.
Adding oxaliplatin to either regimen increases toxicity and does not improve efficacy, judging from results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol RO4 trial that were reported at the annual Gastrointestinal Cancers Symposium sponsored by the American Society of Clinical Oncology.
According to the National Surgical Adjuvant Breast Project (NSABP) B17 protocol, 80% of DCIS cases were nonpalpable (13).
Study Control Trastuzumab Reduction in DFS arm arm relative risk hazard of recurrence ratio NSABP B-31 AC [right AC [right arrow] T arrow] TH Joint analysis 0.48 (N = 2700) NCCTG 52% N9831 AC [right AC [right arrow] T arrow] TH (N = 3300) HERA Any Trastuzumab (N = 5090) 1 year 46% 0.54 BCIRG 006 AC [right AC [right 40% 0.49 arrow] D arrow] DH 33% 0.61 (N = 3150) DCH FINHer D [right DH [right arrow] FEC arrow] FEC (N = 232) V [right VH [right 0.42 arrow] FEC arrow] FEC NSABP, National Surgical Adjuvant Breast and Bowel Project; NCCTG, North Central Cancer Treatment Group; HERA, Herceptin Adjuvant Trial; BCIRG, Breast Cancer International Research Group; FINHer, Finland Herceptin Study.
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial.